Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus
Authors' conclusion
Zoledronate, denosumab and teriparatide reduce the risk of falls that might contribute to their anti-fracture efficacy.
Study context
- Population
- Postmenopausal women (≥ 50 years) with T2D and high risk of fragility fracturesmean age 64.2 ± 6.7 years
- Participants
- 129 women
- Comparison
- Zoledronate, denosumab or teriparatide vs standard of care for 72 weeks
- Primary endpoint
- Risk of falls assessed with the FRAS questionnaire (change from baseline)
- Follow-up
- 72 weeks
Primary result
As reported in the abstract
Change in FRAS from baseline (within-group)
| Group | P (significant reduction) | P (no improvement) |
|---|---|---|
| Teriparatide | p = 0.002 | |
| Zoledronate | p = 0.004 | |
| Denosumab | p = 0.004 | |
| Control | p = 0.875 |
P (significant reduction)
Teriparatidep = 0.002
Zoledronatep = 0.004
Denosumabp = 0.004
Control— not stated in the abstract
P (no improvement)
Teriparatide— not stated in the abstract
Zoledronate— not stated in the abstract
Denosumab— not stated in the abstract
Controlp = 0.875
Further findings
| Outcome | P value |
|---|---|
| Participants with more than one fall in last 12 months · 72 weeksTeriparatide, Zoledronate, Denosumab vs Control | between-group p = 0.033 |
Participants with more than one fall in last 12 months · 72 weeks
- Reduced in teriparatide, zoledronate and denosumab arms; increased in control arm
Glycaemic status, renal function, calcium and vitamin D status · 72 weeks
- Either unchanged over 72 weeks or did not correlate with change in FRAS
Original publication
Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. Published 30 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →